iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024

https://www.globenewswire.com/news-release/2024/05/10/2879601/0/en/iTeos-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html

– Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201
– Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy
– GSK to provide update on GALAXIES program at upcoming investor event in June
– RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close
– Pro forma cash and investment balance of $715 million as of March 31, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.